Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Patients Who Discontinued Prior Checkpoint Therapy or Completed CCTG Studies
NCT03847649Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2020
- Primary completion
- Apr 2030
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in cancer (3 cohorts), sponsored by Canadian Cancer Trials Group. Primary endpoints: Number and severity of adverse events at 2 years and Facilitate continued treatment with durvalumab (+/- Tremelimumab) at 2 years. Started Mar 2020; status: recruiting.
02
Drugs
durvalumab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03847649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847649.